Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Dividends Paid - Common (2019)

BridgeBio Pharma's Dividends Paid - Common history spans 1 years, with the latest figure at $54.0 million for Q3 2019.

  • For Q3 2019, Dividends Paid - Common changed N/A year-over-year to $54.0 million; the TTM value through Dec 2019 reached $55.0 million, changed N/A, while the annual FY2020 figure was $5.0 million, 90.91% down from the prior year.
  • Dividends Paid - Common for Q3 2019 was $54.0 million at BridgeBio Pharma, up from $997000.0 in the prior quarter.
  • Across five years, Dividends Paid - Common topped out at $54.0 million in Q3 2019 and bottomed at $997000.0 in Q1 2019.